From Schizophrenia to Cancer | GenomeWeb

From Schizophrenia to Cancer

Premium

A new study in Cell published by researchers at McMaster University suggests that a drug commonly used to treat ailments like schizophrenia might also be beneficial for cancer patients, reports PsychCentral's Rick Nauert. The drug, a dopamine receptor antagonist, seems to influence cancer stem cells to differentiate into more benign cell types, Nauert says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.